November - 2022

NEWS

Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

Ymmunobio Appoints New Chief Operating Officer

Ymmunobio Accepted into Innosuisse Core Coaching

Dr. Katrin Rupalla Interviewed by Global Business Reports

Drug Discovery & Development

Fierce Biotech: Appointment of Michel Janicot

Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy ...

Authors: Katrin Rupalla, Michel Janicot, Alexej Schmidt, Iris Helfrich, Bernhard B. Singer Full Title: Novel, immune agonistic CEACAM1/5...